Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Discovery

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
• Current treatments like surgery and temozolomide (TMZ) face challenges due to drug resistance and recurrence.
• There is a critical need for advanced models to accelerate the development of new GBM therapies.

Purpose of the Study:

• To establish a microgel-based culture system for glioblastoma (GBM) cells.
• To evaluate the utility of microgels for drug screening and therapeutic response assessment.
• To enable high-throughput screening of potential GBM treatments.

Main Methods:

• Encapsulation of GBM cells within gelatin and polyethylene glycol (PEG) microgels.
• Assessment of microgel composition effects on cell morphology and metabolic activity.
• Quantification of TMZ drug response in microgel cultures.
• Integration of microgels with liquid handling systems for high-throughput screening.

Main Results:

• Microgel composition influences GBM cell morphology.
• GBM cells maintain metabolic activity and exhibit predictable drug response kinetics in microgels.
• The microgel system effectively quantifies responses to single and metronomic TMZ dosing.
• Microgels are compatible with liquid handlers for automated, high-throughput drug screening.

Conclusions:

• Microgels provide a tailorable 3D environment for culturing GBM cells.
• This microgel platform facilitates physiologically relevant drug screening and accelerates therapeutic discovery for glioblastoma.
• The developed method supports high-throughput screening, addressing the urgent need for new GBM treatments.